Your Cart is Empty

Back To Shop

Testosterone Enanthate 200mg 10ml – Watson Steroid in USA



Every 1ml. Continue: Testosterone Enanthate 200 mg.


Testosterone, the main sexual androgen, is responsible for the development and maintenance of male secondary sexual characteristics, exerting an important anabolic action.

This last property contributes, above all, to the acceleration of the growth process in puberty by stimulating bone growth and modulating the welding process of the epiphysis of long bones.

In normal man, it stimulates the activity of the enzyme RNA polymerase and the synthesis of specific RNA, resulting in an increase in protein production.

Testosterone stimulates erythrocyte production because it favors the synthesis of erythropoiesis-stimulating factors.

Testosterone Enanthate 200mg 10ml – Watson Steroid in USA



Congenital or acquired primary hypogonadism: When there is testicular insufficiency due to cryptorchidism, bilateral torsion, testicular absence syndrome or orchidectomy.

Hypogonadotrophic hypogonadism: When there is congenital or acquired deficiency of LH-RH (luteinizing hormone-releasing hormone) or hypothalamic-pituitary due to surgeries, traumas, tumors or radiation.

Delayed puberty: When there is a family pattern of delayed puberty, not secondary to a pathological disorder, in patients who did not respond to psychological support therapy.

Male Climacteric: As a restorative therapy in impotence or other symptoms associated with this disorder, when the etiology is due to a confirmed androgen deficiency.

Severe malnutrition.

Specific anemias: aplastic myelofibrous anemia, myelosclerosis, agnogenic myeloid metaplasia, hypoplastic anemias caused by malignancy or myelotoxic drugs.

Inoperable carcinoma of the breast: As secondary, tertiary palliative treatment of metastatic breast cancer in women with hormone-receptive tumors or those who have shown previous response to hormonal therapy.

Adverse reactions:

The following adverse reactions require medical monitoring:

Virilization and menstrual irregularities in women, bladder irritability, gynecomastia. Anaphylaxis, edema, erythrocytosis, gastrointestinal irritation, hypercalcemia and polycythemia, androgenic alopecia, seborrhea and acne in men and women. Carcinoma prostatic hypertrophy and increased sexual desire.

Adverse reactions are: Constipation, nausea, diarrhea, infection, redness, pain or irritation at the injection site, changes in libido, stomach pain, difficulty sleeping, impotence, testicular atrophy, headaches, anxiety, depression, generalized paresthesia , sleep apnea, skin rash.


It is contraindicated in patients with breast cancer in men, diagnosed or suspected prostate cancer or adenoma, severe heart, liver or kidney failure, in prepubertal or aggressive individuals, pregnancy, hypercalcemia.


Hypogonadism, climacteric or impotence (male replacement therapy): 50 to 400 mg I.M. every 2 to 4 weeks.

Male delayed puberty (replacement therapy): 25 to 200 mg every 2 to 4 weeks, for a period usually limited to 6 months.

Antineoplastic, in inoperable breast cancer (female): 200 to 400 mg I.M. every 2 to 4 weeks.

Cautions and Warnings:

In the palliative treatment of breast cancer, do not continue therapy if after 3 months the disease continues again or hypocalcemia was verified in any phase of it.

Androgen therapy in women, although of short duration, can produce virilization, particularly vocal and hairy.

Androgen therapy is inadvisable to improve athletic performance. In children, this drug should be used with caution due to adverse effects on the bone maturation process, which may be accelerated without producing compensatory gain in linear growth.

When male patients over 50 years of age are treated with androgens, the risk of prostate enlargement or the development of prostate cancer is increased. For this reason, prostate and blood tests are frequently performed before prescribing androgens for men of this age.

Oligospermia, azoospermia or reduced sperm function may occur during long-term treatment, resulting in possible infertility, with spontaneous remission after discontinuation of treatment.

Patients with benign prostatic hypertrophy may develop acute urethral obstruction, requiring immediate discontinuation of medication.

Serum and urinary calcium levels should be frequently determined in women with metastatic breast carcinoma under treatment with Testosterone.

During treatment in prepubertal children, bone X-rays should be taken every 6 months.

In patients with acute intermittent porphyria, androgens may precipitate attacks of this condition.

It is usually preferable to start treatment with full doses and adjust later to individual characteristics.

Drug interactions:

Testosterone may interact with the following drugs:

Adenocorticoids, glycocorticoids or mineralocorticoids: corticotrophin, sodium-containing foods or drugs (may increase the risk of edema and predispose to acne).

Oral antidiabetics or insulin: (because there may be a reduction in serum glucose levels).


Hepatotoxic drugs: (hepatotoxicity is increased).


Frequent doses can trigger symptoms of slow remission, as it is a long acting medication. Immediate discontinuation of the medication is recommended.


The use of a wet needle or syringe can cause cloudiness of the solution that does not affect the effectiveness of the medicine. If crystals form in the blisters, gentle heating by rubbing between hands or shaking may dissolve the crystals.

The intramuscular injection should be administered deep into the gluteal or deltoid muscle. Do not administer intravenously.
Store at 15 – 30°C and protect from freezing. Shake before using.

Buy Testosterone Enanthate steroid USA.


Your Cart is Empty

Back To Shop